Progesterone During IVF: Luteal Phase Support
Progesterone supplementation is essential for luteal phase support in IVF cycles, with vaginal progesterone being the preferred first-line route of administration, typically started on the day of oocyte retrieval or the day after, and continued until 8-12 weeks of gestation once pregnancy is confirmed.
Route of Administration
Vaginal progesterone is the optimal choice for luteal phase support in IVF cycles 1. This route has been definitively shown to be equally efficacious to intramuscular preparations while being better tolerated by patients 2. The evidence supporting vaginal administration is consistent across multiple guidelines and research studies, with approximately 90% of Italian ART centers using this route 3, and 80% of clinicians worldwide preferring vaginal-only administration 4.
Alternative Routes
When vaginal administration is contraindicated or not tolerated:
- Intramuscular progesterone remains an effective alternative, though associated with more injection site reactions and lower patient satisfaction 2
- Subcutaneous progesterone (25 mg daily) has demonstrated equivalent efficacy and safety compared to vaginal preparations, with no significant differences in ongoing pregnancy rates, live birth rates, or OHSS risk 5
- Oral progesterone is emerging as a viable option, with recent evidence showing reassuring safety profiles, though this represents a shift from traditional practice 4
Timing and Initiation
Begin progesterone supplementation on the day of oocyte retrieval or the day after 1. This timing is supported by 96% of Italian ART centers 3 and represents the standard approach across most protocols.
Cycle-Specific Considerations
For frozen embryo transfer (FET) cycles:
- In natural or ovarian stimulation cycles: Start progesterone after ovulation or luteinization 1
- In artificial cycles: Begin progesterone on the day of endometrial transformation 1
- Note that luteal support is not available for oocyte retrieval cycles in FET after PGT-M 1
Dosage
The specific dosage varies by route of administration:
Vaginal progesterone:
- 90-100 mg daily (gel formulation) 5
- 100 mg twice daily (capsules) 5
- 200 mg daily for 10-12 days per month (micronized progesterone) 6
Intramuscular progesterone:
- Standard dosing as per institutional protocols 2
Subcutaneous progesterone:
- 25 mg daily 5
Important Caveat on Dosing
Higher dosages are often used in frozen cycles compared to fresh cycles, with 72.7% of centers combining vaginal with injectable routes when a combined approach is required 3. This reflects real-world practice patterns that may differ from published protocols.
Duration of Treatment
Continue progesterone until 8-12 weeks of gestation once pregnancy is confirmed by ultrasound detection of a viable intrauterine fetus 1, 3, 4.
Cycle-Specific Duration Guidelines
Natural or ovarian stimulation cycles:
- Continue luteal support for 1-3 weeks after pregnancy confirmation 1
Artificial cycles:
- Continue estrogen and progesterone at original doses for 3-4 weeks after pregnancy confirmation
- Gradually reduce dosage over 2 weeks before complete discontinuation 1
Evidence-Practice Gap
Despite lack of strong evidence supporting continuation until 12 weeks, 52% of clinicians continue progesterone until 12 weeks' gestation 4, highlighting a significant divergence between evidence-based recommendations and real-world practice. The more conservative approach of 8-10 weeks is followed by only 35% of respondents 4.
Combined Approaches
When a single route is insufficient or not tolerated, vaginal progesterone combined with injectable routes is the most common combination strategy, used by 72.7% of centers employing combined approaches 3.
Special Populations and Considerations
For patients with antiphospholipid antibodies (aPL) or antiphospholipid syndrome (APS):
- Prophylactic anticoagulation with heparin or LMWH is strongly recommended during ART procedures due to thrombosis risk from elevated estrogen levels 7
- This is separate from but complementary to progesterone supplementation
For patients with premature ovarian insufficiency:
- Transvaginal progesterone has proven effective for maintaining luteal phase endometrial integrity for embryo implantation 6
Key Clinical Pitfalls to Avoid
Do not measure serum FSH levels to monitor progesterone adequacy - FSH is regulated by both estrogen and inhibin, making it an inappropriate marker 6
Do not discontinue progesterone prematurely - Even though the corpus luteum typically takes over progesterone production, the supraphysiological ovarian stimulation in IVF disrupts normal luteal function 8, 2
Avoid using hCG for luteal support when OHSS risk is present - While hCG supplementation shows comparable pregnancy rates to progesterone, it significantly increases OHSS risk 2
Do not assume all progesterone formulations are equivalent - Pharmacokinetics vary significantly between routes, affecting both efficacy and tolerability 8
Evidence Quality and Consensus
The recommendations are primarily based on moderate to low-quality evidence 1, 2, 4, with significant heterogeneity in study designs and outcomes. The 2023 Chinese experts' consensus guideline 1 provides the most recent structured approach, though it acknowledges that specific dosing should reference previous consensus guidelines. The persistent gap between evidence-based recommendations and clinical practice 4 suggests that individualized approaches based on patient tolerance and clinic-specific protocols remain common, though vaginal progesterone as first-line therapy represents the strongest consensus position.